Phaseline

Targets › SCGB2A1

SCGB2A1 (Mammaglobin-B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones. (UniProt, O75556)

Open in Phaseline: the race on SCGB2A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Washington University School of MedicineMammaglobin-A DNA Vaccine
DNA vaccine encoding mammaglobin-A (SCGB2A1), a breast cancer-associated antigen; designed
SCGB2A1Phase 1Breast CancerAug 2028

Conditions

Breast Cancer (1)

Modalities

other (1)

Companies

Washington University School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.